BioCryst Pharmaceuticals, Inc. - Common Stock (BCRX)

Guidance rose as cost cuts from site closures started to take hold.

BioCryst Pharmaceuticals (NASDAQ:BCRX) reported third-quarter results marked by growth in ORLADEYO revenue, higher profitability and progress across its hereditary angioedema, or HAE, portfolio, while maintaining its full-year ORLADEYO revenue outlook following a specialty-pharmacy transition. ORLA

BioCryst Pharmaceuticals (NASDAQ:BCRX) is shifting its strategy toward external innovation as it seeks to expand beyond its ORLADEYO hereditary angioedema, or HAE, franchise, newly appointed Chief Executive Officer Charlie Gayer said at a Morgan Stanley event. Gayer, who became CEO on Jan. 1, said

Moderna, Pharvaris and AbbVie span short, mid and long-term healthcare setups, from melanoma data to a Phase 3 catalyst and 13 straight years of dividend hikes.

ORLADEYO revenue hit $158.2M with 10% growth as pediatric launch exceeded expectations.

BioCryst Pharmaceuticals (NASDAQ:BCRX) reported second-quarter results marked by growth in ORLADEYO revenue, the start of shipments for its pediatric oral-pellet formulation, and completion of enrollment in its pivotal navenibart trial for hereditary angioedema, or HAE. President and CEO Charlie Ga

BioCryst Pharmaceuticals (NASDAQ:BCRX) CEO Charlie Gayer said the company remains on track with its commercial and development plans during a Jefferies fireside chat, highlighting continued growth expectations for hereditary angioedema drug ORLADEYO, progress for late-stage HAE candidate navenibart

BioCryst Pharma (NASDAQ:BCRX) reported strong Q1 earnings, reaffirmed FY2026 sales guidance, and received positive price target changes from analysts.

BioCryst (BCRX) Q1 2026 Earnings Transcript

The company has solid potential with its development of drugs targeting muscle disorders.

BioCryst (BCRX) Q3 2025 Earnings Call Transcript

Retail investors are preparing for another busy week of earnings season with more than 1,600 companies set to report through Friday.

BioCryst Q3 2025 results: Earnings beat estimates with $0.06 EPS, but revenue of $159.4M missed forecasts. ORLADEYO sales grew 37%.

BioCryst will acquire Astria Therapeutics for $700 million to expand its HAE portfolio with navenibart, aiming for double-digit revenue growth.

Carlsbad, CA – October 8, 2025 – Ionis Pharmaceuticals (NASDAQ:IONS) is currently witnessing a remarkable surge in its stock value, nearing a six-year high. This impressive ascent is largely driven by the company's recent strategic guidance, which forecasts over $5 billion in potential annual peak sales from its robust pipeline of

FDA approved Ionis' Dawnzera for hereditary angioedema, showing up to 87% attack reduction and strong results in switch patients.